ABP Live on MSN3h
Genetic Testing And Lung Cancer: Assessing Risk Factors
Lung cancer is the top cause of cancer-related deaths globally, more prevalent in men, and ranks third among women. Both ...
The American Journal of Managed Care21m
Tailored Management Needed for Male Patients With NSCLC After Surgery
Male sex was also shown to be an independent risk factor for longer hospital stays and increased hospitalization costs at ...
The Montana Standard19h
Intermountain Health encourages more lung cancer screenings: Take this quiz to assess your risk factors
Content by Intermountain Health Regional Communications. Did you know that raising awareness and encouraging screening can ...
Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug
Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.
Targeted Oncology18h
FDA Approval Sought for Dato-DXd in EGFR-Mutated NSCLC
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...
Affimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 14, 2024 Affimed N.V. beats earnings expectations. Reported EPS is $-1.03, ...
Frontiers8h
Advancing NSCLC Treatment: Overcoming Challenges in Immune Checkpoint Inhibitor Therapy
Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative therapeutic ...
Immutep stock jumps 11% on positive data for eftilagimod alpha
Shares of Immutep (NASDAQ:IMMP) climbed 11% Thursday after the Australian company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. Immutep (IMMP) said ...